Analysis of parameters of purine metabolism in patients with diabetes mellitus type 2

A.O. Chernyaeva; M.R. Mykytyuk; Yu.I.  Karachentsev

doi:10.26641/2307-0404.2023.4.293972

Authors

A.O. Chernyaeva SI «V. Danilevsky Institute for endocrine pathology problems of the National Academy of Medical sciences of Ukraine», Alchevskykh str. 10, Kharkiv, 61002, Ukraine https://orcid.org/0000-0002-2812-3323
M.R. Mykytyuk SI «V. Danilevsky Institute for endocrine pathology problems of the National Academy of Medical sciences of Ukraine», Alchevskykh str. 10, Kharkiv, 61002, Ukraine https://orcid.org/0000-0002-6169-7628
Yu.I. Karachentsev SI «V. Danilevsky Institute for endocrine pathology problems of the National Academy of Medical sciences of Ukraine», Alchevskykh str. 10, Kharkiv, 61002, Ukraine https://orcid.org/0000-0003-1317-6999

DOI:

https://doi.org/10.26641/2307-0404.2023.4.293972

Keywords:

type 2 diabetes, obesity, uric acid, purine metabolism

Abstract

The aim of this research is to comprehensively analyze the current state of purine metabolism as well as assess its features in patients with diabetes mellitus type 2, taking into account the clinical and metabolic polymorphism of the disease. The authors examined 327 patients with diabetes mellitus type 2 (144 men and 183 women), a group of individuals with an average age of 57.8±10.1 years. The average duration of the disease was (9.3±7.3) years. All subjects received oral hypoglycemic therapy. The researchers determined anthropometric indicators, indicators of carbohydrate metabolism, concentration of creatinine, uric acid, parameters of the blood lipid spectrum, purine bases, activity of xanthine oxidase and hypoxanthine-guanine-phosphoribosyltransferase in the blood. In the course of the study the authors verified excretion of uric acid and creatinine renal uric acid, fractional clearance of uric acid, total tubular reabsorption of uric acid and coefficient of complete degradation of purine bases. Using the software complex "Statgraphics Centurion 18.0", we statistically analyzed the obtained data. The research showed that a decrease in assimilation, increased oxidation of purine bases due to the activation of xanthine oxidase, and a decrease in their reutilization by inhibiting the activity of hypoxanthine-guanine-phosphoribosyltransferase cause the high intensity of purine catabolism in patients with diabetes mellitus type 2. Hyperuricemia (28.0%), increased creatinine renal uric acid (62.3%), increased coefficient of complete degradation of purine bases (41.6%), activity of xanthine oxidase (38.8%) and inhibition of hypoxanthine-guanine-phosphoribosyltransferase activity (50.3%) dominate in the structure of disorders of purine bases in patients with diabetes mellitus type 2. We found that more than 50% of the subjects had high concentrations of purine bases in the blood. Purine bases concentrations in the blood of patients with diabetes mellitus type 2 closely correlate with each other and with the activity of xanthine oxidase and do not correlate with the level of uricemia, the level of uricemia does not correlate with the level of uric acid excretion. That is, the concentration of uric acid in the blood of patients with diabetes mellitus type 2 does not objectively reflect its production in the body. Patients with diabetes mellitus type 2 with obesity associate hyperuricemia with significantly lower creatinine renal uric acid and fractional clearance of uric acid as well as activation of the anabolic pathway of purine bases deposition.

References

Yu W, Cheng JD. Uric Acid and Cardiovascular Disease: An Update From Molecular Mechanism to Clinical Perspective. Front Pharmacol. 2020;11:582680. doi: https://doi.org/10.3389/fphar.2020.582680

Yip K, Cohen RE, Pillinger MH. Asymptomatic hyperuricemia: is it really asymptomatic? Curr Opin Rheumatol. 2020;32(1):71-9. doi: https://doi.org/10.1097/BOR.0000000000000679

Li B, Chen L, Hu X, et al. Association of Serum Uric Acid With All-Cause and Cardiovascular Mortality in Diabetes. Diabetes Care. 2023;46(2):425-33. doi: https://doi.org/10.2337/dc22-1339

Jiao Z, Chen Y, Xie Y, Li Y, Li Z. Metformin pro-tects against insulin resistance induced by high uric acid in cardiomyocytes via AMPK signalling pathways in vitro and in vivo. J Cell Mol Med. 2021;25(14):6733-45. doi: https://doi.org/10.1111/jcmm.16677

Lu J, He Y, Cui L, et al. Hyperuricemia Predispo-ses to the Onset of Diabetes via Promoting Pancreatic β-Cell Death in Uricase-Deficient Male Mice. Diabetes. 2020;69(6):1149-63. doi: https://doi.org/10.2337/db19-0704

Ghasemi A. Uric acid-induced pancreatic β-cell dysfunction. BMC Endocr Disord. 2021;21(1):24. doi: https://doi.org/10.1186/s12902-021-00698-6

Russo E, Viazzi F, Pontremoli R, et al. Association of uric acid with kidney function and albuminuria: the Uric Acid Right for heArt Health (URRAH) Project. J Nephrol. 2022;35(1):211-21. doi: https://doi.org/10.1007/s40620-021-00985-4

Cherniaieva AO. [Hyperuricemia as a marker of the intensity of lipid peroxidation in the population]. Aktualni problemy suchasnoi medytsyny: Visnyk Ukrainskoi medychnoi stomatolohichnoi akademii. 2020;20(3):152-8. Ukrainian. doi: https://doi.org/10.31718/2077-1096.20.3.152

Furuhashi M. New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity. Am J Physiol Endocrinol Metab. 2020;319(5):E827-34. doi: https://doi.org/10.1152/ajpendo.00378.2020

Bayot ML, Lopes JE, Naidoo P. Clinical Laboratory. 2022. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2023 Feb 14]. PMID: 30570979. Available from: https://pubmed.ncbi.nlm.nih.gov/30570979/

Kozarich JW. Welcome to Biochemistry Volu-me 1: No Hyphen Required. Biochemistry. 2021;60(46):3427-8. doi: https://doi.org/10.1021/acs.biochem.1c00569

Hricovíni M, Owens RJ, Bak A, et al. Chemistry towards Biology-Instruct: Snapshot. Int J Mol Sci. 2022;23(23):14815. doi: https://doi.org/10.3390/ijms232314815

Honskyi YaI, Maksymchuk TP. [Human bioche-mistry: a textbook]. Ternopil: TDMU; 2019. 732 р. Ukrainian.

Kawaguchi M, Taniguchi A. [Life-oriented Chemistry in Pharmaceutical Sciences]. Yakugaku Zasshi. 2019;139(2):261-2. Japanese. doi: https://doi.org/10.1248/yakushi.18-00174-F

Schepartz A. Introducing "Future of Biochemistry: The International Issue". Biochemistry. 2019;58(1):1-6. doi: https://doi.org/10.1021/acs.biochem.8b01293

Matli B, Schulz A, Koeck T, et al. Distribution of HOMA-IR in a population-based cohort and proposal for reference intervals. Clin Chem Lab Med. 2021;59(11):1844-51. doi: https://doi.org/10.1515/cclm-2021-0643

Shi J, Lindo EG, Baird GS, et al. Calculating estimated glomerular filtration rate without the race correction factor: Observations at a large academic medical system. Clin Chim Acta. 2021;520:16-22. doi: https://doi.org/10.1016/j.cca.2021.05.022

Townsend MH, Tellez Freitas CM, Larsen D, et al. Hypoxanthine Guanine Phosphoribosyltransferase expression is negatively correlated with immune activity through its regulation of purine synthesis. Immunobiology. 2020;225(3):151931. doi: https://doi.org/10.1016/j.imbio.2020.151931

Choi ST, Song JS, Kim SJ, et al. The Utility of the Random Urine Uric Acid-to-Creatinine Ratio for Patients with Gout Who Need Uricosuric Agents: Retrospective Cross-Sectional Study. J Korean Med Sci. 2020;35(13):e95. doi: https://doi.org/10.3346/jkms.2020.35.e95

Peacock JL, Peacock PL. Oxford Hadbook of Medical Statistics. 2nd ed. Oxford University Press, UK; 2020. 640 p. doi: https://doi.org/10.1093/med/9780198743583.001.0001

Su H, Liu T, Li Y, et al. Serum uric acid and its change with the risk of type 2 diabetes: A prospective study in China. Prim Care Diabetes. 2021;15(6):1002-6. doi: https://doi.org/10.1016/j.pcd.2021.06.010

Zinych O, Shuprovych A, Prybyla O, et al. [Pecu-lia¬rities of the anabolic-catabolic balance of purines in patients with type 2 diabetes with different metabolic phenotypes]. Рroblemy endokrynnoi patolohii. 2023;80(1):22-9. Ukrainian. doi: https://doi.org/10.21856/j-PEP.2023.1.03

Liu J, Chen L, Yuan H, et al. Survey on uric acid in Chinese subjects with essential hypertension (SUCCESS): a nationwide cross-sectional study. Ann Transl Med. 2021;9(1):27. doi: https://doi.org/10.21037/atm-20-3458

Woyesa SB, Hirigo AT, Wube TB. Hyperuricemia and metabolic syndrome in type 2 diabetes mellitus pa-tients at Hawassa university comprehensive specialized hos¬pital, South West Ethiopia. BMC Endocr Disord. 2017;17(1):76. doi: https://doi.org/10.1186/s12902-017-0226-y

Zhang Q, Zhang C, Song X, et al. A longitudinal cohort based association study between uric acid level and metabolic syndrome in Chinese Han urban male population. BMC Public Health. 2012;12:419. doi: https://doi.org/10.1186/1471-2458-12-419

Li C, Hsieh MC, Chang SJ. Metabolic syndrome, diabetes, and hyperuricemia. Curr Opin Rheumatol. 2013;25(2):210-6. doi: https://doi.org/10.1097/BOR.0b013e32835d951e/

İnanir M. Serum uric acid (SUA) in morbidly obese patients and its relationship with metabolic syndrome. Aging Male. 2020;23(5):1165-9. doi: https://doi.org/10.1080/13685538.2020.1713742/

Li W, Wang Y, Ouyang S, et al. Association Between Serum Uric Acid Level and Carotid Atherosclerosis and Metabolic Syndrome in Patients With Type 2 Diabetes Mellitus. Front Endocrinol (Lausanne). 2022;13:890305. doi: https://doi.org/10.3389/fendo.2022.890305